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Treatment of screen detected ductal carcinoma in situ: a silver lining
within a grey cloud?
I.S. Fentiman
ICRF Clinical Oncology Unit, Guy's Hospital, London SE] 9RT, UK.
The outlook is stormy for breast cancer screening in Britain.
A deep depression, centred over Scotland, threatens to
dampen the spirits of even the most forceful proponents of
screening mammography. Recently published 7-year mor-
tality data have shown a reduction of 17% in the screened
group of the Edinburgh trial (Roberts et al., 1990). This
amounts to only half the mortality reduction reported in the
HIP and two county trials (Shapiro et al., 1982; Tabar et al.,
1985). In part this was because only 61% of women accepted
the offer of screening and this fell to 53% by the third year
visit. If this proves to be a reflection of national compliance,
the prospects would be overcast for even modest denting of
mortality from breast cancer.
Of the cancers diagnosed as a result of screening 10-15%
prove to be of non-infiltrating type, mostly ductal carcinoma
in situ (DCIS). Thus, in the UK, some 700-800 cases of
DCIS would be diagnosed annually. How should these cases
be treated? Nobody knows. Faced with this dilemma, various
approaches are possible. The first is to treat all patients by
the standard treatment, total mastectomy, with or without
immediate reconstruction. This will achieve 'cure', that is
avoidance of death from metastatic breast carcinoma in up
to 98% of cases. However, such success is obtained by a
procedure which may represent overtreatment for some
patients. In contrast, subcutaneous mastectomy constitutes
sub-optimal treatment for DCIS. In this issue, the experience
of the Royal Marsden Hospital is reported with over 50% of
patients treated by subcutaneous mastectomy developing
subsequent relapse of disease, half of which were infiltrating
lesions (Price et al., 1990).
A second approach is to treat such patients by wide
excision and providing that there is pathological confirmation
that DCIS has been completely excised, to follow the patients
closely by regular clinical examination and mammography.
In a series of 79 patients with mammographically detected
DCIS with pathological confirmation of complete local
excision (CLE) and measuring up to 2.5 cm in extent, recur-
rence of DCIS occurred in eight (10%) but progression to
infiltrating carcinoma occurred in only four (5%) (Lagios et
al., 1989). A third and more exciting approach is to deter-
mine whether the progression of DCIS to infiltrating car-
cinoma can be inhibited by either endocrine or radio-
therapeutic manipulations. This would need to be investi-
gated by a prospective randomised trial, and such a study
has been designed by a working party set up by the Breast
Cancer Trials Coordinating Subcommittee (BCTCS).
This multidisciplinary group, under the chairmanship of
Professor C.A. Joslin, have written a protocol for a national
trial of DCIS as part of the NHS breast cancer screening
programme. Although clinical trials are underway in the
USA (NSABP B-17) and Europe (EORTC 10853), no data
on outcome were available (van Dongen et al., 1989). The
trial protocol which evolved has taken account of patho-
logical, radiological, surgical, radiotherapeutic, statistical and
ethical considerations.
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The diagnosis of DCIS should be made on a paraffin fixed
section. Although fine needle aspiration cytology may show
differences between DCIS and infiltrating ductal carcinoma,
such as hypocellularity, presence of benign epithelial cells and
macrophages in DCIS, these cannot be relied on to distin-
guish the two (Wang et al., 1989). Frozen section may also
lead to difficulties in distinguishing DCIS from infiltrating
carcinoma, or occasionally from benign lesions such as
sclerosing adenosis. With properly fixed material the diag-
nosis of DCIS may be made, and the predominant lesion can
be subtyped as comedo, solid, cribriform, papillary, clinging
or intracystic papillary.
In addition, small cell and large cell variants may be
distinguished, the latter usually being components of comedo
carcinomas, which are most likely to over-express the proto-
oncogene C-erbB-2 (van de Vijver et al., 1988). This intro-
duces heterogeneity into the classification of DCIS and
emphasises the need for large studies in order that sub-group
analysis may be undertaken, so that invasive diathesis may
be quantified.
To reduce administration, histopathological information
will be recorded by the pathologist on the form which will be
in routine use in the screening programme. The pathologist
will be asked to determine whether the area of DCIS has
been completely excised, either at primary surgery, usually as
a result of needle localisation, or at subsequent wide excision.
Complete excision implies that the DCIS does not extent to
the specimen margin which will have been marked post-
operatively with indian ink.
The main aim of the trial is to compare the effectiveness of
complete local excision alone with complete local excision
followed by radiotherapy to the entire breast, and/or tamoxi-
fen 20 mg daily for 5 years, in reducing the incidence of
subsequent invasive breast carcinoma. A secondary aim is to
compare, within the treatment arms, the incidence of subse-
quent DCIS in the ipsilateral breast distant from the original
lesion, and in the contralateral breast.
The study comprises a factorial 2 x 2 design
CLE alone
CLE + XRT
CLE + tamoxifen
CLE + XRT + tamoxifen
Patients with DCIS and Paget's disease of the nipple will be
excluded. Those with lobular carcinoma in situ (LCIS) or
atypical hyperplasia without DCIS will not be eligible. As
presently required all cases will have had specimen radiology
and histological confirmation of clear margins. The trial is
aimed at screen detected DCIS. However, symptomatic cases
with DCIS who are treated by surgeons in participating
assessment centres can also be entered.
In order to make the trial as widely acceptable as possible,
surgeons can, if they wish, put their patients into one half of
the trial, that is CLE alone versus CLE and XRT, or alterna-
tively CLE alone versus CLE and tamoxifen. If the surgeon
believes that all his or her patients should receive radio-
therapy, this can also be accommodated with a randomisa-
tion to receive or not receive tamoxifen. However, it is hoped
that the majority of cases will be entered into the full trial,
resulting in four balanced treatment groups: (1) complete
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local excision (CLE) with no further local or systemic
therapy; (2) CLE followed by supervoltage radiotherapy to
the ipsilateral breast to a dose of 50 Gy in 5 weeks, or its
equivalent, starting no later than 8 weeks after the final
surgical procedure; (3) CLE followed by tamoxifen 20 mg
once daily for 5 years, starting no later than 8 weeks after the
final surgical procedure; (4) CLE followed by both
radiotherapy and tamoxifen.
Patients receiving radiotherapy will receive a homogeneous
dose to the entire breast without skin bolus, without boost to
the excision site and without treatment to the gland fields.
Supervoltage irradiation will be given, using tangential fields.
Although different fractionation schemes are allowed the
recommended dose is 50 Gy in 25 fractions over 5 weeks.
Frequency of follow-up depends upon the individual
surgeon's judgement although recommendations have been
made. In order to simplify documentation follow-up forms
will be sought only once a year, and mammography will
be performed annually for the first 7 years and thereafter
biennially.
On the assumption that there would be a 10% local
relapse rate at 5 years after CLE alone, 250 entrants will be
needed in each arm of the trial, giving a total entry of 1,000
patients, in order to have an 80% power of detecting a 50%
reduction from either main treatment effect, that is whether
tamoxifen or external radiation can reduce the progress to
infiltrating carcinoma from 10% to 5%.
Recruitment to the trial will be reviewed after 2 years, in
order to determine the practicality ofcontinuing with all four
treatment arms. Once 40 breast cancer events have been
recorded the event rates in each arm will be compared and
the results reported blindly to a data review committee.
The ethical aspects of this trial are wide-reaching. Since
there is no acceptable body of information on management
of screen detected DCIS, this represents a new disease entity,
for which no standard treatment can be used as a yardstick.
Each arm of the trial may convey benefits and carry other
risks. Thus, although there may be more risk of progression
to infiltrating carcinoma in those treated by complete local
excision alone, there is no evidence that this affects survival
or suitability for subsequent breast conservation. The effect
of tamoxifen on progression is unknown but adjuvant results
in patients with infiltrating carcinoma do suggest a reduction
in contralateral carcinoma (Cuzick & Baum 1985, Fornander
et al., 1989). Short and medium-term toxicity of tamoxifen is
minimal, and no long-term deleterious effects on bone
mineral or lipoprotein profile have been reported, although
the magnitude of risk of endometrial carcinoma or hepatocel-
lular carcinoma have yet to be quantified (Fentiman &
Powles, 1987). Radiotherapy is of proven value in patients
with invasive carcinoma, but unproven for DCIS, and can be
associated with side-effects such as skin oedema/breast
fibrosis. A possible link between old techniques of chest wall
irradiation and fatal heart attacks many years later has been
reported (Cuzick et al., 1987).
Patients need to be made aware of these uncertainties and
allowed to express their own views. It is up to the surgeon to
explain not just why they are asking their patients to enter
the study, but also why they feel unable to do so.
The difficulties of running a national trial cannot be
underestimated. However, problems are largely logistic rather
than conceptual and should not be allowed to sabotage the
study. The trial is compatible with parallel studies examining
the expression or amplification of proto-oncogenes and DNA
ploidy in relation to malignant progression. A unique
opportunity has arisen to answer very important questions
concerning the biological behaviour of DCIS after apparent
complete local excision. If clinicians, and in particular
surgeons, can make a commitment to enter cases into this
national trial there is a reasonable chance that by the
millenium a satisfactory framework for the treatment of
screen detected DCIS will be available.
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